Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.
Toshiki MasuishiHiroya TaniguchiDaisuke KotaniHideaki BandoYoshito KomatsuEiji ShinozakiTakako Eguchi NakajimaTaroh SatohTomohiro NishinaTaito EsakiMasashi WakabayashiShogo NomuraKoji TakahashiHiromi OnoNami HiranoNoriko FujishiroNozomu FuseAkihiro SatoAtsushi OhtsuTakayuki YoshinoPublished in: ESMO open (2019)
UMIN000031221 and 000031552.